Trial Profile

A Larger Ex-U.S. Double Masked, Vehicle Controlled, Phase 2 Study of ALG-1007 for the Treatment of Dry Eye Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALG 1007 (Primary)
Indications Dry eyes
Focus Therapeutic Use

Most Recent Events

24 Jul 2021 Results published in the Media Release
24 Jul 2021 According to an Allegro Ophthalmics media release, results were presented by Eric D. Donnenfeld, M.D., at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) Annual Meeting in Las Vegas.
19 Jul 2021 According to an Allegro Ophthalmics media release, the company is looking forward to participating in the first live Eyecelerator meeting and sharing the results from this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com